Conbercept ophthalmic injection global phase III clinical subjects into the group completed!

On December 25, 2019, Chengdu Kanghong Pharmaceutical Group Co., Ltd released the progress announcement of the clinical trial project of conbercept ophthalmic injection, as follows: Chengdu Kanghong Biotechnology Co., Ltd., a wholly-owned subsidiary of Chengdu Kanghong Pharmaceutical Group Co., Ltd., started the "one multi center Double blind, randomized, dose range trial to evaluate the efficacy and safety of conbercept ophthalmic injection in the treatment of neovascular age-related macular degeneration As of December 24, 2019, the number of participants in the global phase III clinical trial of conbercept ophthalmic injection for the treatment of wet age-related macular degeneration (namd) has reached 100% of the total number required by the clinical trial protocol Conbercept ophthalmic injection is a receptor antibody fusion protein that specifically inhibits angiogenesis On November 29, 2013, conbercept ophthalmic injection was approved by the State Food and Drug Administration of China as a drug registration approval for the treatment of wet age-related macular degeneration in China On September 30, 2016, Kanghong bio obtained the notice of U.S Food and Drug Administration on allowing conbercept ophthalmic injection to carry out phase III clinical trial of wet age-related macular degeneration (Wamd) in the United States; on April 19, 2018, Kanghong bio obtained the notice of U.S Food and drug administration Notice of administration on reviewing and approving the special protocol assessment of neovascular age-related macular degeneration clinical trial conducted in the United States by conbercept intravitreal ophthalmic injection Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.